速递｜Nature子刊发表先为达埃诺格鲁肽注射液Ⅲ期EECOH-1研究结果

Core Viewpoint - The article discusses the successful results of the phase III clinical trial (EECOH-1) for Enoglutide injection, a GLP-1 receptor agonist developed by Xianweida Biotech, which shows significant benefits in lowering blood sugar and weight in adults with type 2 diabetes [4][7]. Group 1: Clinical Trial Results - The EECOH-1 study involved 211 adult participants with poorly controlled blood sugar after dietary and exercise interventions, conducted across 32 centers in China [7]. - Participants were randomly assigned to receive either Enoglutide injection at doses of 0.6mg or 1.2mg, or a placebo, for 24 weeks, followed by an additional 28 weeks of treatment for the placebo group [7]. - After 24 weeks, both doses of Enoglutide significantly reduced HbA1c levels compared to the placebo, with the 1.2mg group achieving a reduction of 2.43% [7]. Group 2: Efficacy and Safety - The proportion of patients achieving HbA1c levels below 7.0% was significantly higher in the Enoglutide groups, with the 1.2mg group reaching 80.3% [7]. - Enoglutide also led to significant weight loss, with reductions of 4.51% and 4.74% for the 0.6mg and 1.2mg groups, respectively, after 24 weeks [8]. - The treatment improved various cardiovascular metabolic risk indicators and showed good overall safety and tolerability, with most adverse events being mild to moderate [8].